Male Hypogonadism Market Report 2026

The male hypogonadism market size has grown strongly in recent years. It will grow from $3.95 billion in 2025 to $4.17 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing prevalence of hypogonadism, rising awareness of testosterone deficiency, growth in aging male population, advancements in hormone replacement therapies, increased physician adoption of diagnostic testing.

The male hypogonadism market size is expected to see strong growth in the next few years. It will grow to $5.34 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to expansion of personalized medicine, integration of ai in diagnosis and treatment, growth in telehealth services, rising adoption of advanced drug delivery systems, increasing investment in male hormonal research. Major trends in the forecast period include personalized testosterone therapy, minimally invasive drug delivery systems, awareness programs for male hormonal health, integration of telemedicine in hormonal treatment, expansion of chronic disease management services.

The rising infertility rates are expected to drive the growth of the male hypogonadism market. Infertility refers to the inability to conceive after 12 months or longer of frequent, unprotected sexual activity, and it can affect both men and women. Male hypogonadism, which can result in reduced sperm production and infertility, is one of the potential causes of male infertility. As male infertility becomes more prevalent, the demand for treatments targeting male hypogonadism is expected to grow. For example, in February 2023, the Office for National Statistics, a UK-based government agency, reported that 31.8% of all live births in England and Wales were to non-UK-born mothers, an increase from 30.3% in 2022. Additionally, 37.3% of live births were to parents where either one or both were born outside the UK, up from 35.8% in 2022. This increase in infertility rates contributes to the growth of the male hypogonadism market.

Major companies in the male hypogonadism market are concentrating on developing innovative solutions, such as digital-first platforms, to engage patients through telemedicine, provide educational resources, and simplify access to treatments. These approaches are transforming the management of male hypogonadism by improving patient support and expanding access to therapy. For example, in October 2024, LifeMD, Inc., a U.S.-based provider of virtual primary care services, launched TestoRx, a direct-to-consumer testosterone replacement therapy telehealth service under its Rex MD men’s health brand. The program includes an initial virtual consultation and required blood testing, treatment options covering both testosterone replacement and alternative therapies to stimulate natural hormone production, and ongoing telehealth visits with follow-up care.

In October 2023, ADVANZ Pharma, a UK-based developer of specialty and legacy pharmaceutical assets, acquired the global rights to Tostran from Kyowa Kirin for an undisclosed amount. This acquisition allowed ADVANZ to strengthen its men’s health portfolio by gaining access to a clinically established testosterone gel used in the treatment of male hypogonadism. Kyowa Kirin, a Japan-based pharmaceutical company, specializes in developing innovative biologics and specialty medicines in areas such as oncology, nephrology, immunology, and the central nervous system.

Major companies operating in the male hypogonadism market are Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Antares Pharma Inc., Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, TherapeuticsMD Inc., Viking Therapeutics Inc., Shionogi & Co. Ltd., Ferring Pharmaceuticals.

North America was the largest region in the male hypogonadism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the male hypogonadism market by increasing the cost of imported pharmaceutical ingredients and advanced delivery devices, particularly impacting injectable and transdermal patch segments. Regions such as North America and Europe, which rely heavily on imported components, face higher production costs and supply chain delays. While tariffs pose challenges, they have encouraged local manufacturing initiatives and innovation in cost-efficient therapies, ultimately driving market resilience and development of alternative sourcing strategies.

The male hypogonadism market research report is one of a series of new reports that provides male hypogonadism market statistics, including male hypogonadism industry global market size, regional shares, competitors with a male hypogonadism market share, detailed male hypogonadism market segments, market trends and opportunities, and any further data you may need to thrive in the male hypogonadism industry. This male hypogonadism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Male hypogonadism is a condition in which the body produces insufficient amounts of testosterone, the primary male sex hormone. Testosterone is crucial for the development and growth of men during puberty.

The main types of male hypogonadism include Klinefelter syndrome, Kallmann syndrome, pituitary disorders, and others. Klinefelter syndrome is a hereditary disorder that occurs when boys are born with an extra copy of the X chromosome. Treatment for male hypogonadism involves testosterone therapy and gonadotropin-releasing hormone therapy, delivered through various methods such as topical gels, injections, transdermal patches, and other forms.

The male hypogonadism market includes revenues earned by entities through hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.